Cell-free DNA in Acute Stroke

University Hospital, Basel, Switzerland200 enrolled

Overview

Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Stroke

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan) * 18 years of age Exclusion Criteria: * Patients currently undergoing immunological therapies. * Patients with immunological diseases * Patients with systemic infections at the time of admission

Locations (1)

University Hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

Stroke Etiology

Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology

Time frame: at day 1

Secondary Outcomes

Correlation cfDNA concentration and perfusion outcome

cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including perfusion outcome

Time frame: at day 1

Correlation cfDNA concentration and secondary embolism

cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including secondary embolism

Time frame: at day 1

Correlation cfDNA concentration and thrombus fragmentation.

cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including thrombus fragmentation

Time frame: at day 1

Measures of cfDNA as a marker of systemic inflammation

to correlate cfDNA amount in blood and thrombi

Time frame: at day 1

90-day functional outcomes

to examine the association between cfDNA concentrations in blood and thrombi with 90-day functional outcomes. To assess functional outcomes, the modified Rankin Scale (mRS) is evaluated via a structured telephone interview on day 90. A favorable outcome is defined as an mRS score of 0 to 2 points, while an unfavorable outcome is defined as an mRS score of 3 to 5 points.

Time frame: up to 3 month

Cell-free DNA in Acute Stroke

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts